BERWYN, Pa.--(BUSINESS WIRE)--QR Pharma, Inc. (QR) is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment after acute brain injury like concussions, head trauma and stroke or in chronic degeneration like Alzheimer’s and Parkinson’s disease. QR and the University of California Los Angeles (UCLA) announce today they received a US Army grant in the amount of $3,000,000 to study Posiphen® in two models of traumatic brain injury (TBI).
Help employers find you! Check out all the jobs and post your resume.
